• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

ISCOMATRIX? adjuvant promotes epitope spreading and antibody affinity maturation of influenza A H7N9 virus like particle vaccine that correlate with v

tetano

Editor, Senior Moderator
Vaccine. 2015 Jun 17. pii: S0264-410X(15)00836-1. doi: 10.1016/j.vaccine.2015.06.047. [Epub ahead of print]
[h=1]ISCOMATRIX? adjuvant promotes epitope spreading and antibody affinity maturation of influenza A H7N9 virus like particle vaccine that correlate with virus neutralization in humans.[/h] Chung KY[SUP]1[/SUP], Coyle EM[SUP]1[/SUP], Jani D[SUP]2[/SUP], King LR[SUP]1[/SUP], Bhardwaj R[SUP]1[/SUP], Fries L[SUP]2[/SUP], Smith G[SUP]2[/SUP], Glenn G[SUP]2[/SUP], Golding H[SUP]1[/SUP], Khurana S[SUP]3[/SUP].
[h=3]Author information[/h]

[h=3]Abstract[/h] In a previously reported phase I clinical trial, subjects vaccinated with two doses of an unadjuvanted H7N9 virus like particle (VLP) vaccine responded poorly (15.6% seroconversion rates with 45μg hemagglutinin (HA) dose). In contrast, 80.6% of subjects receiving H7N9 VLP vaccine (5μg HA) with ISCOMATRIX? adjuvant developed hemagglutination-inhibition (HI) responses. To better understand the role of adjuvant, complete antibody epitope repertoires of post-vaccination sera were investigated using Whole Genome Fragment Phage Display Library (GFPDL). In addition, antibody affinity maturation following vaccination was measured against HA1 and HA2 antigenic domains using real time Surface Plasmon Resonance (SPR) based kinetic assays. Unadjuvanted H7N9-VLP vaccine generated primarily antibodies targeting the C-terminus of the HA1 domain, predicted to be mostly buried on the native HA spikes, while adjuvanted VLP vaccine generated antibodies against large epitopes in the HA1 spanning the receptor binding domain (RBD). SPR analysis using a functional H7-HA1 domain demonstrated that sera from adjuvanted H7N9-VLP vaccine induced higher total binding antibodies and significantly higher antibody affinity maturation to HA1 compared to sera from unadjuvanted vaccine. Total antibody binding and affinity to the HA1 (but not HA2) domain correlated with HI and neutralization titers. This study demonstrates that ISCOMATRIX? adjuvanted vaccine promotes higher quality antibody immune response against avian influenza in na?ve humans.
Copyright ? 2015. Published by Elsevier Ltd.


[h=4]KEYWORDS:[/h] Adjuvant; Antibody affinity; Epitope; H7N7; H7N9; Hemagglutinin; ISCOMATRIX (ISCO); Influenza; Neutralization; Pandemic; Phage display; Vaccine; Virus

PMID: 26093202 [PubMed - as supplied by publisher]
 
Back
Top Bottom